Dec 29, 2011 FDA's approval of class-wide REMS puts ONSOLIS in an improved competitive position
|
|
|
Nov 28, 2011 Decision supports BDSI's position regarding the invalidity of MonoSol's '588 Patent
|
|
|
|
|
Nov 10, 2011 Positive data would allow for initiation of pivotal bioequivalence study in January
|
Nov 7, 2011 BDSI to receive $300,000 milestone payment
|
Oct 25, 2011 New independent director brings extensive biotech industry and legal experience to BDSI Board
|
Sep 28, 2011 Primary endpoint in overall population not achieved but significant pain control observed in the opioid "experienced" group of patients (p=0.067)
|
Sep 6, 2011 Promising data allows for the potential initiation of pivotal bioequivalence study by year-end
|
|
|
Aug 22, 2011 Product Available in Canada This Quarter Through Meda Valeant
|
Jul 25, 2011 Reporting of top-line efficacy results anticipated in mid to late September
|
|
|
|
|
|
|
May 5, 2011 Company presents Thursday, May 12 at 3:30 P.M. EDT
|
Apr 5, 2011 Reporting of top-line efficacy results remains on target for third-quarter 2011
|
|
|
Mar 11, 2011 Business update call to be held today at 10:00 a.m. Eastern Time
|
|
|
Mar 2, 2011 Definitive bioequivalence study results compared to Suboxone anticipated by year-end
|
Feb 17, 2011 Reporting of top-line study results on target for third-quarter
|
| |
